Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid MalignanciesDavid Olmos, Sarah P. Blagden, Douglas S. Barker et al.|Clinical Cancer Research|2011Cited by 168
Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S studyHenriette Farkas, William Sheridan, O. Fain et al.|Clinical and Translational Allergy|2021Cited by 54
Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumorsDavid Olmos, Sarah P. Blagden, Alicia J. Allred et al.|Journal of Clinical Oncology|2009Cited by 22
Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.Jean‐Charles Soria, Michael Millward, Hui Gan et al.|Journal of Clinical Oncology|2012Cited by 14
431 POSTER A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumorsSarah P. Blagden, Johann S. de Bono, David Olmos et al.|European Journal of Cancer Supplements|2008Cited by 4